{"id":745540,"date":"2017-06-03T07:30:00","date_gmt":"2017-06-03T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\/"},"modified":"2025-11-07T01:26:28","modified_gmt":"2025-11-07T06:26:28","slug":"new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\/","title":{"rendered":"New Data Show Durability of Response for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless of Tumor Type"},"content":{"rendered":"<p class=\"bwalignc\">       First-Time Findings from KEYNOTE-164 and KEYNOTE-158, to Be Presented        at ASCO, Further Support the Utility of MSI-H and dMMR as Predictive        Biomarkers for Tumor-Agnostic Treatment Approach with KEYTRUDA     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the first presentation of findings from KEYNOTE-164 and<br \/>\n      KEYNOTE-158, two phase 2 studies evaluating KEYTRUDA<sup>\u00ae <\/sup>(pembrolizumab),<br \/>\n      the company\u2019s anti-PD-1 therapy, in patients with advanced<br \/>\n      microsatellite instability-high (MSI-H) or mismatch repair deficient<br \/>\n      (dMMR) solid tumors. The studies showed overall response rates (ORR),<br \/>\n      regardless of histology, with ORR between 28 percent (95% CI, 17-41) and<br \/>\n      38 percent (95% CI, 27-49) across patients with MSI-H\/dMMR colorectal<br \/>\n      cancer (CRC) and other advanced MSI-H\/dMMR solid tumors, respectively.<br \/>\n      These findings will be presented on Monday, June 5 at the 2017 American<br \/>\n      Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract<br \/>\n      #3071).\n    <\/p>\n<p>\n      \u201cThese important data build on the research to date showing clinically<br \/>\n      meaningful responses with pembrolizumab (KEYTRUDA) monotherapy across a<br \/>\n      wide range of tumors with MSI-H or dMMR status in patients whose disease<br \/>\n      is locally advanced or metastatic,\u201d said Dr. Luis A. Diaz, Jr., head of<br \/>\n      the division of solid tumor oncology, Memorial Sloan Kettering Cancer<br \/>\n      Center. \u201cMoreover, these data confirm the initial findings we made<br \/>\n      demonstrating the value of MSI-H or dMMR tumor status as a predictive<br \/>\n      biomarker for KEYTRUDA for these difficult-to-treat cancers.\u201d\n    <\/p>\n<p>\n      \u201cThese data exemplify our commitment to advancing the use of biomarkers<br \/>\n      to help identify patients most likely to benefit from KEYTRUDA,\u201d said<br \/>\n      Dr. Roger Dansey, senior vice president and therapeutic area head,<br \/>\n      oncology late-stage development, Merck Research Laboratories.\n    <\/p>\n<p>\n      The KEYTRUDA (pembrolizumab) clinical development program includes more<br \/>\n      than 30 tumor types in more than 500 clinical trials, including more<br \/>\n      than 300 trials that combine KEYTRUDA with other cancer treatments.<br \/>\n      Merck\u2019s immuno-oncology clinical development program includes multiple<br \/>\n      registration-enabling studies investigating KEYTRUDA as a monotherapy in<br \/>\n      MSI-H and dMMR cancers.\n    <\/p>\n<p>\n      <b>Key Findings from KEYNOTE-164 and KEYNOTE-158 Studies<\/b>\n    <\/p>\n<p>\n      KEYNOTE-164 and KEYNOTE-158 are ongoing global, open-label,<br \/>\n      non-randomized, multi-cohort, multi-center phase 2 studies evaluating<br \/>\n      KEYTRUDA (200 mg every three weeks) in patients with advanced MSI-H or<br \/>\n      dMMR solid tumors. KEYNOTE-164 is enrolling patients with previously<br \/>\n      treated, unresectable locally advanced or metastatic MSI-H or dMMR CRC<br \/>\n      who received two or more prior therapies that included fluoropyrimidine,<br \/>\n      irinotecan, and oxaliplatin. KEYNOTE-158 is enrolling patients with any<br \/>\n      advanced MSI-H solid tumor, with the exception of CRC, who had received<br \/>\n      one or more prior therapies. MSI-H or dMMR tumor status is determined<br \/>\n      using local laboratory-developed, polymerase chain reaction (PCR) tests<br \/>\n      for MSI-H status or immunohistochemistry (IHC) tests for dMMR. Tumor<br \/>\n      response is assessed every nine weeks per Response Evaluation Criteria<br \/>\n      in Solid Tumors (RECIST) v1.1 by independent, central, blinded<br \/>\n      radiographic review. The primary endpoint of the studies is ORR;<br \/>\n      secondary endpoints include duration of response, progression-free<br \/>\n      survival (PFS), overall survival (OS) and safety.\n    <\/p>\n<p>\n      Of the 61 patients with advanced CRC who were enrolled in KEYNOTE-164<br \/>\n      (as of Feb. 10, 2017), the ORR was 28 percent (n=17\/61) (95% CI, 17-41)<br \/>\n      \u2013 with zero complete responses and 17 partial responses; fourteen had<br \/>\n      stable disease and 28 had progressive disease \u2013 for an overall disease<br \/>\n      control rate of 51 percent (n=31\/61) (95% CI, 38-64). Median time to<br \/>\n      response was four months (range: 2-10).\n    <\/p>\n<p>\n      Of the 77 patients with any advanced solid tumor, excluding CRC and with<br \/>\n      \u226527 weeks of follow-up, who were enrolled in KEYNOTE-158 (as of Jan. 27,<br \/>\n      2017), the ORR was 38 percent (n=29\/77) (95% CI, 27-49) \u2013 with two<br \/>\n      complete responses and 27 partial responses; sixteen had stable disease<br \/>\n      and 24 had progressive disease \u2013 for an overall disease control rate of<br \/>\n      58 percent (n=45\/77) (95% CI, 47-70). Median time to response was 2<br \/>\n      months (range: 1-4).\n    <\/p>\n<p>\n      For the PFS analysis, in patients with CRC the estimated 6-month rate<br \/>\n      was 43 percent and the 12-month rate was 34 percent \u2013 with a median PFS<br \/>\n      of 2.3 months (95% CI, 2.1-8.1); in patients with any advanced solid<br \/>\n      tumor, excluding CRC, the estimated 6-month rate was 45 percent \u2013 with a<br \/>\n      median PFS of 4.3 months (95% CI, 3.1-not reached). For the OS analysis,<br \/>\n      in patients with CRC the estimated 6-month rate was 87 percent and the<br \/>\n      12-month rate was 72 percent \u2013 with a median OS not yet reached; in<br \/>\n      patients with any advanced solid tumor, excluding CRC, the estimated<br \/>\n      6-month rate was 73 percent \u2013 with a median OS not yet reached (95% CI,<br \/>\n      9.2-not reached). Median follow-up was 13.2 months (range: 0-17) and 6.1<br \/>\n      months (range: 1-12), respectively. At the time of analysis, median<br \/>\n      duration of response had not been reached in either study (range:<br \/>\n      2.9+-12.5+ and range: 2.4+-9.2+, respectively).\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA (pembrolizumab) was consistent with that<br \/>\n      observed in previously reported studies. In patients with CRC, the<br \/>\n      treatment-related adverse events observed to date (any grade occurring<br \/>\n      in 10% or more of patients) were arthralgia (n=10), nausea (n=9),<br \/>\n      diarrhea (n=8), asthenia (n=7), pruritus (n=7) and fatigue (n=6); these<br \/>\n      included Grade 3-4 treatment-related fatigue (n=2) and asthenia (n=1).<br \/>\n      Immune-mediated adverse events of Grade 3-4 were pancreatitis (n=3),<br \/>\n      hepatitis (n=1) and severe skin toxicity (n=1). There were no<br \/>\n      treatment-related deaths.\n    <\/p>\n<p>\n      In patients with any advanced solid tumor, excluding CRC, the<br \/>\n      treatment-related adverse events observed to date (any grade occurring<br \/>\n      in 10% or more of patients) were fatigue (n=8), pruritus (n=7), asthenia<br \/>\n      (n=7), diarrhea (n=7), nausea (n=6) and arthralgia (n=2); these include<br \/>\n      Grade 3-4 asthenia (n=1) and diarrhea (n=1). Immune-mediated adverse<br \/>\n      events of Grade 3-4 toxicity were severe skin toxicity (n=2),<br \/>\n      hyperthyroidism (n=1), pneumonitis (n=1), fulminant type 1 diabetes<br \/>\n      mellitus (n=1) and Guillain-Barre Syndrome (n=1). There was one death<br \/>\n      attributed to treatment-related pneumonia by investigator.\n    <\/p>\n<p>\n      <b>About Microsatellite Instability and DNA Mismatch Repair<\/b>\n    <\/p>\n<p>\n      Microsatellites are short repetitive sequences of DNA found throughout<br \/>\n      the genome.&nbsp;Microsatellite instability \u2013 or MSI \u2013 is caused by a<br \/>\n      deficiency in the cell\u2019s ability to repair errors in the DNA sequence<br \/>\n      (DNA mismatch repair) that occur during cell division, leading to a<br \/>\n      characteristic change in microsatellite repeats.&nbsp;MSI is detected<br \/>\n      indirectly by demonstrating absence of expression of mismatch repair<br \/>\n      proteins by IHC, or more directly by PCR-based amplification of specific<br \/>\n      microsatellite repeats. MSI-H (microsatellite instability-high) is<br \/>\n      already an established biomarker in certain types of cancer. Patients<br \/>\n      determined to have mismatch repair deficiency (dMMR) are biologically<br \/>\n      the same population as those with MSI-H status. MSI-H\/dMMR occurs in a<br \/>\n      variety of cancers across all stages.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Studies of KEYTRUDA \u2013 from the largest immuno-oncology program in the<br \/>\n      industry with more than 500 trials \u2013 include a wide variety of cancers<br \/>\n      and treatment settings. The KEYTRUDA clinical program seeks to<br \/>\n      understand factors that predict a patient\u2019s likelihood of benefiting<br \/>\n      from treatment with KEYTRUDA, including the exploration of several<br \/>\n      different biomarkers across a broad range of tumors.\n    <\/p>\n<p>\n      KEYTRUDA is administered as an intravenous infusion over 30 minutes<br \/>\n      every three weeks for the approved indications. KEYTRUDA for injection<br \/>\n      is supplied in a 100 mg single-dose vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab)<\/b> <b>Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab), in combination with pemetrexed and<br \/>\n      carboplatin, is indicated for the first-line treatment of patients with<br \/>\n      metastatic nonsquamous NSCLC. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and progression-free<br \/>\n      survival. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with<br \/>\n      locally advanced or metastatic urothelial carcinoma who are not eligible<br \/>\n      for cisplatin-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who have disease progression<br \/>\n      during or following platinum-containing chemotherapy or within 12 months<br \/>\n      of neoadjuvant or adjuvant treatment with platinum-containing<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      pediatric patients with MSI-H cancer, KEYTRUDA is administered at a dose<br \/>\n      of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      (pembrolizumab) for Grade 2; permanently discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799 patients<br \/>\n      receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) can cause type 1 diabetes mellitus, including<br \/>\n      diabetic ketoacidosis, which have been reported in 6 (0.2%) of 2799<br \/>\n      patients. Monitor patients for hyperglycemia or other signs and symptoms<br \/>\n      of diabetes. Administer insulin for type 1 diabetes, and withhold<br \/>\n      KEYTRUDA and administer antihyperglycemics in patients with severe<br \/>\n      hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma. In addition,<br \/>\n      myelitis and myocarditis were reported in other clinical trials,<br \/>\n      including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA. Treatment with KEYTRUDA may increase the risk of rejection<br \/>\n      in solid organ transplant recipients. Consider the benefit of treatment<br \/>\n      with KEYTRUDA vs the risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA (pembrolizumab).\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      on any trial, 6 patients (26%) developed graft-versus-host-disease<br \/>\n      (GVHD), one of which was fatal, and 2 patients (9%) developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning, one of which was fatal. Cases of fatal hyperacute GVHD<br \/>\n      after allogeneic HSCT have also been reported in patients with lymphoma<br \/>\n      who received a PD-1 receptor\u2013blocking antibody before transplantation.<br \/>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue, pruritis, diarrhea, decreased appetite, rash, pyrexia, cough,<br \/>\n      dyspnea, musculoskeletal pain, constipation, and nausea.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. In a study, 40<br \/>\n      pediatric patients (16 children aged 2 years to younger than 12 years<br \/>\n      and 24 adolescents ages 12 years to 18 years) with advanced melanoma,<br \/>\n      lymphoma, or PD-L1\u2013positive advanced, relapsed, or refractory solid<br \/>\n      tumors, were administered KEYTRUDA 2 mg\/kg every 3 weeks. Patients<br \/>\n      received KEYTRUDA for a median of 3 doses (range 1-17 doses), with 34<br \/>\n      patients (85%) receiving KEYTRUDA for 2 doses or more. The safety<br \/>\n      profile in these pediatric patients was similar to that seen in adults<br \/>\n      treated with KEYTRUDA. Toxicities that occurred at a higher rate (\u226515%<br \/>\n      difference) in these patients when compared to adults under 65 years of<br \/>\n      age were fatigue (45%), vomiting (38%), abdominal pain (28%),<br \/>\n      hypertransaminasemia (28%), and hyponatremia (18%).\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 500 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51569354&amp;newsitemid=20170603005022&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=3a380d7e2c0e2b48b45b191921c5aca1\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51569354&amp;newsitemid=20170603005022&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=15ab362dc9f1e09f00942ce2d1580e1d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51569354&amp;newsitemid=20170603005022&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=fda7f42c63b34b9f2eee113cec044d55\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51569354&amp;newsitemid=20170603005022&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=8b18b081dbd2a30728a1ab8e0e289f65\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51569354&amp;newsitemid=20170603005022&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=e8d649ff9de20aceade0566e5d6aa815\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51569354&amp;newsitemid=20170603005022&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=50ac810becf4bb813bfe82493467770b\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51569354&amp;newsitemid=20170603005022&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=750baf7be01e22a31364070b133d48cc\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51569354&amp;newsitemid=20170603005022&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=6c73155c368c96a1d290589e6e887f89\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51569354&amp;newsitemid=20170603005022&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=9&amp;md5=00cf87c686f12a9a175b7f8b0b999bd4\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51569354&amp;newsitemid=20170603005022&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=10&amp;md5=3750bf483a2bda0fb0f210b999c8e07b\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170603005022r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Teresa        Mueller, 908-740-1884<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>First-Time Findings from KEYNOTE-164 and KEYNOTE-158, to Be Presented at ASCO, Further Support the Utility of MSI-H and dMMR as Predictive Biomarkers for Tumor-Agnostic Treatment Approach with KEYTRUDA Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of findings from KEYNOTE-164 and KEYNOTE-158, two phase 2 studies evaluating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with advanced microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors. The studies showed overall response rates (ORR), regardless of histology, with ORR between 28 percent (95% CI, 17-41) and 38 percent (95% CI, 27-49) across patients with MSI-H\/dMMR colorectal cancer (CRC) and other advanced MSI-H\/dMMR solid tumors, respectively. These findings will be presented on Monday, June 5 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract #3071). \u201cThese important data<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[149,53,64,55,289],"class_list":["post-745540","news_item","type-news_item","status-publish","hentry","tag-asco","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Data Show Durability of Response for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless of Tumor Type - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Data Show Durability of Response for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless of Tumor Type - Merck.com\" \/>\n<meta property=\"og:description\" content=\"First-Time Findings from KEYNOTE-164 and KEYNOTE-158, to Be Presented at ASCO, Further Support the Utility of MSI-H and dMMR as Predictive Biomarkers for Tumor-Agnostic Treatment Approach with KEYTRUDA Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of findings from KEYNOTE-164 and KEYNOTE-158, two phase 2 studies evaluating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with advanced microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors. The studies showed overall response rates (ORR), regardless of histology, with ORR between 28 percent (95% CI, 17-41) and 38 percent (95% CI, 27-49) across patients with MSI-H\/dMMR colorectal cancer (CRC) and other advanced MSI-H\/dMMR solid tumors, respectively. These findings will be presented on Monday, June 5 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract #3071). \u201cThese important data\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"18 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\\\/\",\"name\":\"New Data Show Durability of Response for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless of Tumor Type - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-06-03T07:30:00+00:00\",\"dateModified\":\"2025-11-07T06:26:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Data Show Durability of Response for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless of Tumor Type\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Data Show Durability of Response for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless of Tumor Type - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\/","og_locale":"en_US","og_type":"article","og_title":"New Data Show Durability of Response for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless of Tumor Type - Merck.com","og_description":"First-Time Findings from KEYNOTE-164 and KEYNOTE-158, to Be Presented at ASCO, Further Support the Utility of MSI-H and dMMR as Predictive Biomarkers for Tumor-Agnostic Treatment Approach with KEYTRUDA Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of findings from KEYNOTE-164 and KEYNOTE-158, two phase 2 studies evaluating KEYTRUDA\u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, in patients with advanced microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors. The studies showed overall response rates (ORR), regardless of histology, with ORR between 28 percent (95% CI, 17-41) and 38 percent (95% CI, 27-49) across patients with MSI-H\/dMMR colorectal cancer (CRC) and other advanced MSI-H\/dMMR solid tumors, respectively. These findings will be presented on Monday, June 5 at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Abstract #3071). \u201cThese important data","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:28+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"18 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\/","name":"New Data Show Durability of Response for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless of Tumor Type - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-06-03T07:30:00+00:00","dateModified":"2025-11-07T06:26:28+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-show-durability-of-response-for-mercks-keytruda-pembrolizumab-in-advanced-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-solid-tumors-regardless\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New Data Show Durability of Response for Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) in Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors, Regardless of Tumor Type"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"72893ff0-a38f-4b8a-b73e-2523899b592f","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/New-Data-Show-Durability-of-Response-for-Mercks-KEYTRUDA-pembrolizumab-in-Advanced-Microsatellite-Instability-High-MSI-H-or-Mismatch--4VUDR.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745540\/revisions"}],"predecessor-version":[{"id":3674897,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745540\/revisions\/3674897"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745540"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}